Amarin Future Growth
Future criteria checks 4/6
Amarin is forecast to grow earnings and revenue by 51.2% and 10.1% per annum respectively. EPS is expected to grow by 50.8% per annum. Return on equity is forecast to be -13.3% in 3 years.
Key information
51.2%
Earnings growth rate
50.8%
EPS growth rate
Biotechs earnings growth | 20.6% |
Revenue growth rate | 10.1% |
Future return on equity | -13.3% |
Analyst coverage | Low |
Last updated | 19 Mar 2024 |
Recent future growth updates
Recent updates
Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues As Shares Take 27% Pounding
Mar 12Amarin: Sarissa Is Giving Me Hope Again
Jan 15Improved Revenues Required Before Amarin Corporation plc (NASDAQ:AMRN) Stock's 26% Jump Looks Justified
Jan 03Calculating The Fair Value Of Amarin Corporation plc (NASDAQ:AMRN)
Nov 19Investors Don't See Light At End Of Amarin Corporation plc's (NASDAQ:AMRN) Tunnel
Sep 27We Think Amarin (NASDAQ:AMRN) Can Afford To Drive Business Growth
Jul 18Is Amarin (NASDAQ:AMRN) In A Good Position To Deliver On Growth Plans?
Nov 11Amarin gains as activist Sarissa starts process for special meeting to replace some board members
Oct 11Amarin down 21% on higher than normal daily volume
Aug 22For Amarin, Something Wishful This Way Comes
Aug 14Amarin Q2 2022 Earnings Preview
Aug 02HLS Therapeutics gets reimbursement for Vascepa in Ontario
Jul 25Amarin's Vazkepa medicine gets final guidance from UK body for reimbursement and use
Jul 13Amarin extends losses after Stat report on cardiovascular therapy
Jun 30Amarin: Alex Denner, Health Net, Statin Combo, And Signs Of Better Times
Apr 19Here's Why We're Not At All Concerned With Amarin's (NASDAQ:AMRN) Cash Burn Situation
Feb 23Amarin: Revisiting Old Battles Lost
Feb 02Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 302 | 6 | N/A | 107 | 3 |
12/31/2025 | 233 | -52 | N/A | 66 | 4 |
12/31/2024 | 224 | -61 | 21 | 14 | 5 |
12/31/2023 | 307 | -59 | 6 | 7 | N/A |
9/30/2023 | 322 | -52 | 8 | 9 | N/A |
6/30/2023 | 346 | -38 | -17 | -16 | N/A |
3/31/2023 | 361 | -91 | -89 | -88 | N/A |
12/31/2022 | 369 | -106 | -181 | -180 | N/A |
9/30/2022 | 423 | -92 | -210 | -210 | N/A |
6/30/2022 | 476 | -100 | -196 | -196 | N/A |
3/31/2022 | 536 | -22 | -147 | -147 | N/A |
12/31/2021 | 583 | 8 | -67 | -67 | N/A |
9/30/2021 | 606 | -2 | -77 | -77 | N/A |
6/30/2021 | 620 | 4 | -61 | -61 | N/A |
3/31/2021 | 601 | 1 | -45 | -45 | N/A |
12/31/2020 | 614 | -18 | -22 | -22 | N/A |
9/30/2020 | 590 | -16 | 7 | 8 | N/A |
6/30/2020 | 546 | -13 | 17 | 19 | N/A |
3/31/2020 | 511 | -19 | 30 | 33 | N/A |
12/31/2019 | 430 | -23 | -12 | -9 | N/A |
9/30/2019 | 364 | -63 | -35 | -33 | N/A |
6/30/2019 | 307 | -84 | -83 | -83 | N/A |
3/31/2019 | 259 | -117 | -123 | -123 | N/A |
12/31/2018 | 229 | -116 | -95 | -95 | N/A |
9/30/2018 | 206 | -105 | -65 | -65 | N/A |
6/30/2018 | 198 | -92 | -43 | -43 | N/A |
3/31/2018 | 190 | -71 | -29 | -29 | N/A |
12/31/2017 | 181 | -68 | -33 | -33 | N/A |
9/30/2017 | 166 | -73 | N/A | -50 | N/A |
6/30/2017 | 151 | -78 | N/A | -62 | N/A |
3/31/2017 | 139 | -78 | N/A | -61 | N/A |
12/31/2016 | 130 | -86 | N/A | -72 | N/A |
9/30/2016 | 118 | -81 | N/A | -76 | N/A |
6/30/2016 | 107 | -97 | N/A | -80 | N/A |
3/31/2016 | 91 | -147 | N/A | -96 | N/A |
12/31/2015 | 82 | -149 | N/A | -84 | N/A |
9/30/2015 | 72 | -147 | N/A | -74 | N/A |
6/30/2015 | 64 | -141 | N/A | -72 | N/A |
3/31/2015 | 59 | -62 | N/A | -57 | N/A |
12/31/2014 | 54 | -56 | N/A | -75 | N/A |
9/30/2014 | 48 | -52 | N/A | -92 | N/A |
6/30/2014 | 42 | -75 | N/A | -117 | N/A |
3/31/2014 | 35 | -130 | N/A | -158 | N/A |
12/31/2013 | 26 | -166 | N/A | -190 | N/A |
9/30/2013 | 16 | -161 | N/A | -201 | N/A |
6/30/2013 | 8 | -139 | N/A | -196 | N/A |
3/31/2013 | 2 | -153 | N/A | -164 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMRN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: AMRN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AMRN is expected to become profitable in the next 3 years.
Revenue vs Market: AMRN's revenue (10.1% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: AMRN's revenue (10.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AMRN is forecast to be unprofitable in 3 years.